Applied Industrial Technologies to Report Fiscal Fourth Quarter Earnings and Conduct Conference Call on August 14, 2025
The Company will host a conference call at 10 a.m. ET that day to discuss the quarter's results and outlook. A live audio webcast and supplemental presentation can be accessed on our Investor Relations site at https://ir.applied.com. To join by telephone, dial 800-715-9871 (toll free) or 646-307-1963 using conference ID 7270709.
Replays of the call will be available via webcast, as well as by telephone for one week by dialing 800-770-2030 (toll free) using conference ID 7270709.
About Applied ®
Applied Industrial Technologies is a leading value-added distributor and technical solutions provider of industrial motion, fluid power, flow control, automation technologies, and related maintenance supplies. Our leading brands, specialized services, and comprehensive knowledge serve MRO (maintenance, repair, and operations), OEM (original equipment manufacturing), and new system install applications in virtually all industrial markets through our multi-channel capabilities that provide choice, convenience, and expertise. For more information, visit www.applied.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
NVO: Novo Nordisk Stock Climbs After Major FDA Approval
Aug 1 - Novo Nordisk (NYSE:NVO) gained nearly 3% in Friday morning trading after the company secured expanded U.S. approval for its Alhemo injection. The therapy can now help prevent or reduce bleeding episodes in adults and children 12 and older with hemophilia A or B. Warning! GuruFocus has detected 1 Warning Sign with NVO. Previously, Alhemo was only authorized for patients with hemophilia A or B who developed inhibitors. The new decision from the U.S. Food and Drug Administration followed a late?stage clinical trial that demonstrated the drug's safety and ability to lower bleeding risk in a broader patient group. Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming increasingly competitive with gene therapies and new clotting factor treatments, but Novo Nordisk's broader label should reinforce its rare disease portfolio. The company expects Alhemo to contribute to revenue growth in the second half of 2025 as more patients gain access. Investors will watch whether this momentum continues into upcoming quarters as the therapy reaches a larger base of hemophilia patients. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
9 minutes ago
- Business Wire
Lazard Announces Total Consideration for Lazard Group LLC's Cash Tender Offer for Its 3.625% Senior Notes Due 2027
NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today the Total Consideration as set forth in the table below in respect of the previously announced cash tender offer (the 'Tender Offer') of its subsidiary Lazard Group LLC ('Lazard Group') for any and all of its outstanding 3.625% Senior Notes due March 1, 2027 (the 'Notes'). The Tender Offer is being made upon the terms and conditions in the Offer to Purchase dated July 28, 2025. The Tender Offer will expire today at 5:00 p.m. (New York City time), unless extended or terminated as described in the Offer to Purchase (such time and date, as they may be extended, the 'Expiration Time'). Holders of the Notes are urged to carefully read the Offer to Purchase and Notice of Guaranteed Delivery before making any decision with respect to the Tender Offer. As previously announced, in order to be eligible to receive the 'Total Consideration,' holders must (i) validly tender their Notes on or prior to the Expiration Time or (ii) deliver a properly completed Notice of Guaranteed Delivery and all other required documents at or prior to the Expiration Time and validly tender their Notes at or prior to 5:00 p.m. (New York City time) on the second business day after the Expiration Time pursuant to guaranteed delivery procedures. The Total Consideration for each $1,000 principal amount of Notes validly tendered and not validly withdrawn was determined in the manner described in the Offer to Purchase by reference to the fixed spread over the yield to maturity based on the bid side price of the UST Reference Security listed below, calculated by the Dealer Managers (as defined below) for the Tender Offer as of 2:00 p.m. (New York City time) today, the date on which the Tender Offer is currently scheduled to expire, and is set forth in the table below. In addition to the Total Consideration, accrued and unpaid interest up to, but not including, the Settlement Date (as defined below) will be payable in cash on all validly tendered and accepted Notes. Interest will cease to accrue on the Settlement Date for all Notes accepted for purchase in the Tender Offer, including any such Notes tendered through guaranteed delivery procedures. As a result, Notes tendered through the guaranteed delivery procedures will not receive accrued interest from the Settlement Date through the Guaranteed Delivery Settlement Date (as defined below), which is expected to be two business days after the Settlement Date. Payment for Notes validly tendered in the Tender Offer and accepted by Lazard Group for purchase will be made on the date referred to as the 'Settlement Date' or, in the case of Notes tendered through guaranteed delivery procedures, the 'Guaranteed Delivery Settlement Date.' The Settlement Date is expected to occur on the next business day following the Expiration Time, and the Guaranteed Delivery Settlement Date is currently expected to occur on the third business day following the Expiration Time. The closing of the Tender Offer is subject to the satisfaction or waiver of certain conditions as set forth in the Offer to Purchase. Lazard Group reserves the right, subject to applicable law, to (i) waive any and all conditions to the Tender Offer, (ii) extend the Expiration Time, (iii) amend the Tender Offer in any respect (including, without limitation, to change the fixed spread), or (iv) terminate the Tender Offer on or prior to the Expiration Time and return the Notes tendered pursuant thereto, in each case by giving written or oral notice of such extension, amendment, or termination to Global Bondholder Services Corporation, the tender agent (in such capacity, the 'Tender Agent'). This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell the Notes. The Tender Offer is being made solely by means of the Offer to Purchase and Notice of Guaranteed Delivery dated July 28, 2025. The Tender Offer is void in all jurisdictions where it is prohibited. In those jurisdictions where the securities, blue sky, or other laws require the Tender Offer to be made by a licensed broker or dealer, the Tender Offer will be deemed to be made on behalf of Lazard Group by the Dealer Managers or one or more registered brokers or dealers licensed under the laws of such jurisdictions. Citigroup Global Markets Inc. is acting as the lead dealer manager and Lazard Frères & Co. LLC is acting as co-dealer manager (together, the 'Dealer Managers') for the Tender Offer. Requests for documents may be directed to Global Bondholder Services Corporation, the information agent (in such capacity, the 'Information Agent'), by telephone at (212) 430-3774, in writing at Attn: Corporate Actions, 65 Broadway—Suite 404, New York, New York 10006 or by email at contact@ Copies of the Offer Documents are also available at the following website: Questions regarding the Tender Offer may be directed to Citigroup Global Markets Inc. by telephone at (800) 558-3745 (toll-free) or (212) 723-6106 (collect) or in writing at Attn: Liability Management Group, 388 Greenwich Street, Trading 4th Floor, New York, New York 10013. None of Lazard Group or its affiliates, their respective boards of directors, the Dealer Managers, the Tender Agent, the Information Agent or the trustee for the Notes makes any recommendation as to whether holders should tender any of their Notes. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amount of their Notes to tender. About Lazard Founded in 1848, Lazard is one of the world's preeminent financial advisory and asset management firms, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'could,' 'would,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'target,' 'goal,' 'pipeline,' or 'continue,' and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies, business plans and initiatives and anticipated trends in our business. These forward-looking statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. These factors include, but are not limited to, those discussed in our Annual Report on Form 10-K under Item 1A 'Risk Factors,' and also discussed from time to time in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including the following: Adverse general economic conditions or adverse conditions in global or regional financial markets; Changes in international trade policies and practices, including the implementation of tariffs, proposed further tariffs, and responses from other jurisdictions, and the economic impacts, volatility and uncertainty resulting therefrom; A decline in our revenues, for example due to a decline in overall mergers and acquisitions ('M&A') activity, our share of the M&A market or our assets under management ('AUM'); Losses caused by financial or other problems experienced by third parties; Losses due to unidentified or unanticipated risks; A lack of liquidity, i.e., ready access to funds, for use in our businesses; Competitive pressure on our businesses and on our ability to retain and attract employees at current compensation levels; and Changes in relevant tax laws, regulations or treaties or an adverse interpretation of those items. These risks and uncertainties are not exhaustive. Our SEC reports describe additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. As a result, there can be no assurance that the forward-looking statements included in this release will prove to be accurate or correct. Although we believe the statements reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, achievements or events. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this release to conform our prior statements to actual results or revised expectations and we do not intend to do so. Lazard, Inc. is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, Lazard and its operating companies use their websites, and other social media sites to convey information about their businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical and business-related information, and the posting of updates of AUM in various mutual funds, hedge funds and other investment products managed by Lazard Asset Management LLC and Lazard Frères Gestion SAS.
Yahoo
37 minutes ago
- Yahoo
Gildan Activewear Inc (GIL) Q2 2025 Earnings Call Highlights: Record Sales and Strategic Growth ...
Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Gildan Activewear Inc (NYSE:GIL) reported record second quarter sales of $919 million, up 6.5% year-over-year, driven by strong activewear sales growth of 12%. The company achieved a record adjusted diluted EPS of $0.97, marking a 31% increase year-over-year, reflecting a focus on profitable growth. Gildan Activewear Inc (NYSE:GIL) continues to gain market share in key growth categories, supported by strong demand for existing brands and new brand offerings. The company's Bangladesh facility is fully ramped up, contributing to operational efficiency and cost advantages. Gildan Activewear Inc (NYSE:GIL) has been recognized for its commitment to sustainable practices, being named one of Canada's best 50 corporate citizens and featured among Time's world's most sustainable companies. Negative Points International sales were down by 14% year-over-year due to moderated demand in Europe and persistent softness in Asia. Hosiery and underwear sales decreased by 23% compared to the prior year, impacted by broad-based market demand softness and program resets. Operating cash flow decreased to $46 million in the first half of 2025 from $113 million in the first half of 2024, primarily due to higher working capital investments. The company faces challenges from tariffs, although it has implemented pricing actions to mitigate the impact. There is ongoing uncertainty in the macroeconomic environment, which could affect future performance and market conditions. Q & A Highlights Warning! GuruFocus has detected 5 Warning Sign with ELMTY. Q: Can you quantify the shifts in sales from Q3 to Q4 and discuss the impact on the underwear and hosiery business, including the Nike sock pause and the exit from Under Armour? A: (CFO) The second quarter was strong, with activewear sales up 12% year over year. Some sales shifted from Q3 to Q4 due to pricing actions. We expect mid-single-digit growth when combining Q2 and Q3. The underwear and hosiery segment faced headwinds like delayed store sets and market softness, but we anticipate improvement throughout the year. The shifts are not structural and should resolve over time. Q: What changes in the industry landscape are driving momentum in the activewear business, and what opportunities do you see going forward? A: (COO) The industry is experiencing changes due to tariffs and economic conditions, leading customers to seek stable suppliers. Our vertically integrated manufacturing provides stability. We are gaining market share in key categories like ringspun and Comfort Colors. Our US cotton and yarn content offer a competitive advantage against tariffs, and we are adding capacity in Central America to capitalize on future opportunities. Q: How much can you increase throughput in Honduras, and what is the timing and magnitude of this opportunity? A: (CEO) We are adding capacity within existing facilities, expecting a 10% increase overall. This expansion will be completed this year, allowing us to handle future demand and take advantage of tariff-related opportunities. Q: Is the Bangladesh facility running at optimal efficiency, and how do you view its cost savings in various tariff scenarios? A: (CEO) The Bangladesh facility is fully ramped up, contributing to operating margin expansion. We are using US cotton to offset tariff impacts and have flexibility in our supply chain to mitigate tariffs. We are well-positioned to leverage our low-cost manufacturing and innovation pipeline. Q: Can you expand on the pricing actions taken in response to tariff pressures and how competitors have responded? A: (CEO) Pricing varies by customer and product category, with sequential rollouts. The impact is not substantial due to our cost structure. Competitors face similar issues, and we have a competitive advantage with our vertically integrated manufacturing. Price increases are minimal compared to the overall value chain, and we are well-positioned to navigate these challenges. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
